New combo drug for obesity tested in japanese volunteers

NCT ID NCT06297616

Completed Symptom relief Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested the safety of a new drug called LY3841136, given alone or with another drug (tirzepatide), in 128 Japanese adults who are obese or overweight. Researchers monitored side effects and how the body processes the drugs over several months. The goal was to see if the combination is safe and tolerable for weight management.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metabolic disease Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY OVERWEIGHT

Contacts and locations

Locations

Hakata Clinic

Fukuoka, 812-0025, Japan
P-One Clinic

Hachiōji, Tokyo, 192-0071, Japan
Sumida Hospital

Sumida-ku, Tokyo, 130-0004, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.